Carcinoma, Non-Small-Cell Lung Clinical Trial
— TRITONOfficial title:
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Non-Squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON).
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Status | Recruiting |
Enrollment | 280 |
Est. completion date | March 12, 2031 |
Est. primary completion date | August 17, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 130 Years |
Eligibility | Inclusion Criteria: - Histologically or cytologically documented Stage IV non-squamous NSCLC not amenable to curative surgery or radiation. - Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations are also allowed. - Participants must have tumors that lack activating epidermal growth factor receptor mutations and ALK fusions. - No prior chemotherapy or any other systemic therapy for metastatic NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred > 6 months from end of last therapy. - No prior exposure to immune-mediated therapy excluding therapeutic anti-cancer vaccines, within 12 months to randomization. - WHO/ECOG performance status of 0 or 1 at enrollment and randomization. - Minimum life expectancy = 12 weeks at randomization. - At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline and can be accurately measured at baseline as = 10 mm in the longest diameter with Computed Tomography (CT)/CT- Positron Emission Tomography or Magnetic Resonance Imaging and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines. - Adequate organ and bone marrow function: - Negative pregnancy test (urine or serum) for women of child-bearing potential - Female participants must be 1 year post-menopausal, surgically sterile, or using one highly effective form of birth control - Male and Female participants and their partners must use an acceptable method of contraception. - Body weight of > 30 kg Exclusion Criteria: - Any evidence of acute or uncontrolled diseases or history of allogeneic organ transplant. - Mixed small cell lung cancer and NSCLC histology. - Major surgical procedure within 28 days prior to the first dose of the study intervention or an anticipated need for major surgery during the study. - Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], systemic lupus erythematosus, sarcoidosis, granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis [requiring immunosuppressive systemic therapy, eg, methotrexate, steroids], hypophysitis, uveitis, etc), autoimmune pneumonitis and autoimmune myocarditis. The following are exceptions to this criterion: - Participants with vitiligo or alopecia. - Participants with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement. - Any chronic skin condition that does not require systemic therapy. - Participants without active disease in the last 5 years may be included but only after consultation with the Study Clinical Lead. - Participants with celiac disease controlled by diet alone. - Medical contraindication to platinum-based doublet chemotherapy. - History of another primary malignancy except: - Malignancy treated with curative intent with no known active disease = 2 years before the first dose of study intervention and of low potential risk for recurrence - Adequately resected non-melanoma skin cancer and curatively treated in situ disease. - Persistent toxicities (Common Terminology Criteria for Adverse Events [CTCAE] Grade = 2) caused by previous anti-cancer therapy, alopecia and vitiligo are excluded toxicities. - Participants with Grade = 2 neuropathy can be considered based on Investigator's judgement. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by treatment with study intervention in the opinion of the Investigator may be included (eg, hearing loss). - Spinal cord compression unless asymptomatic and stable. - Participant meets the following: - Symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication or arrhythmias controlled by pacemakers may be permitted based on the Investigator judgement with cardiologist consultation recommended. - Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptable. - No radiation therapy is allowed, unless it is 1) definitive radiation that had been administered at least 6 months prior, 2) palliative radiation to brain, with associated criteria for stability or lack of symptoms, or 3) palliative radiation to painful bony lesions (this must comprise less than 30% of the bone marrow) - Patients with suspected brain metastases at screening should have an intravenous (IV) contrast-enhanced MRI (preferred) or IV contrast-enhanced CT/CT-PET of the brain prior to study entry. If brain metastases are detected patients must be treated before randomization. Randomization is only permitted if patients with brain metastases have: - Confirmed stable condition - Returned neurologically to baseline Brain metastases will not be recorded as RECIST target lesions at baseline. - History of leptomeningeal carcinomatosis. - Known to have tested positive for active tuberculosis infection - Known active hepatitis infection, positive HCV antibody, HBsAg, or anti-HBc, at screening. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if PCR is negative for HCV RNA. Participants co-infected with HBV and HCV, or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg and/or anti-HBcAb with detectable HBV DNA); AND - HCV positive (presence of anti-HCV antibodies); OR - HDV positive (presence of anti-HDV antibodies). - Known human immunodeficiency virus (HIV) infection that is not well controlled. - Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention. The following are exceptions to this criterion: - Intranasal, inhaled, topical steroids or local steroid injections (eg, intra-articular injection). - Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent. - Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication, premedication for chemotherapy) or a single dose for palliative purpose (eg, pain control). - Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention. - Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or the follow-up period of an interventional study. - Participants with a known hypersensitivity to any of the study interventions or any of the excipients of the products. - For females only: Currently pregnant (confirmed with positive pregnancy test) or breast-feeding, or who are planning to become pregnant. Female participants should refrain from breastfeeding from enrolment throughout the study and until up to 14 months after the last dose of cisplatin or 180 days after pemetrexed or 90 days after tremelimumab or durvalumab or pembrolizumab, whichever is longer; and during treatment with carboplatin. |
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Albany | Georgia |
United States | Research Site | Albany | New York |
United States | Research Site | Anchorage | Alaska |
United States | Research Site | Atlanta | Georgia |
United States | Research Site | Atlanta | Georgia |
United States | Research Site | Austin | Texas |
United States | Research Site | Bethesda | Maryland |
United States | Research Site | Billings | Montana |
United States | Research Site | Birmingham | Alabama |
United States | Research Site | Bismarck | North Dakota |
United States | Research Site | Bronx | New York |
United States | Research Site | Chandler | Arizona |
United States | Research Site | Charlottesville | Virginia |
United States | Research Site | Chicago | Illinois |
United States | Research Site | Cleveland | Ohio |
United States | Research Site | Columbus | Ohio |
United States | Research Site | Columbus | Georgia |
United States | Research Site | Dallas | Texas |
United States | Research Site | Dallas | Texas |
United States | Research Site | Dayton | Ohio |
United States | Research Site | Denton | Texas |
United States | Research Site | Detroit | Michigan |
United States | Research Site | Evansville | Indiana |
United States | Research Site | Fairfax | Virginia |
United States | Research Site | Farmington Hills | Michigan |
United States | Research Site | Fort Lauderdale | Florida |
United States | Research Site | Fort Worth | Texas |
United States | Research Site | Hershey | Pennsylvania |
United States | Research Site | Houston | Texas |
United States | Research Site | Houston | Texas |
United States | Research Site | Irvine | California |
United States | Research Site | Jupiter | Florida |
United States | Research Site | Kansas City | Missouri |
United States | Research Site | Kansas City | Missouri |
United States | Research Site | La Jolla | California |
United States | Research Site | Lexington | Kentucky |
United States | Research Site | Lexington | Kentucky |
United States | Research Site | Loma Linda | California |
United States | Research Site | Los Alamitos | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Maywood | Illinois |
United States | Research Site | Memphis | Tennessee |
United States | Research Site | Memphis | Tennessee |
United States | Research Site | Milwaukee | Wisconsin |
United States | Research Site | Nashville | Tennessee |
United States | Research Site | New Hyde Park | New York |
United States | Research Site | New York | New York |
United States | Research Site | New York | New York |
United States | Research Site | Northport | New York |
United States | Research Site | Ocala | Florida |
United States | Research Site | Oklahoma City | Oklahoma |
United States | Research Site | Orlando | Florida |
United States | Research Site | Philadelphia | Pennsylvania |
United States | Research Site | Providence | Rhode Island |
United States | Research Site | Richmond | Virginia |
United States | Research Site | Saint Louis | Missouri |
United States | Research Site | Saint Paul | Minnesota |
United States | Research Site | San Antonio | Texas |
United States | Research Site | Santa Monica | California |
United States | Research Site | Shirley | New York |
United States | Research Site | Stony Brook | New York |
United States | Research Site | Syracuse | New York |
United States | Research Site | Tampa | Florida |
United States | Research Site | Toledo | Ohio |
United States | Research Site | Urbana | Illinois |
United States | Research Site | Washington | District of Columbia |
United States | Research Site | Washington | District of Columbia |
United States | Research Site | Westwood | Kansas |
United States | Research Site | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (OS) | OS is defined as the time from randomization until death due to any cause in all participants. | From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months) | |
Primary | OS in subset of randomized participants with STK11 or KEAP1 mutations and/or co-mutations | OS is defined as the time from randomization until death due to any cause in participants with STK11 or KEAP1 mutations and/or co-mutations. | From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months) | |
Secondary | Overall survival at 12 months | OS is defined as the time from randomization until death due to any cause in all participants. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark. | At 12 months | |
Secondary | Overall survival at 24 months | OS is defined as the time from randomization until death due to any cause in all participants. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark. | At 24 months | |
Secondary | Overall survival at 12 months in subset of randomized participants with STK11 or KEAP1 mutation and/or co mutations. | OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark. | At 12 months | |
Secondary | Overall survival at 24 months in subset of randomized participants with STK11 or KEAP1 mutation and/or co mutations. | OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark. | At 24 months | |
Secondary | Overall survival in subset of randomized participants whose PD-L1 status is PD-L1 TC < 1% | OS is defined as the time from randomization until death due to any cause. | From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months) | |
Secondary | Overall survival at 12 months in subset of randomized participants whose PD-L1 status is PD-L1 TC < 1% | OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 12 months landmark. | At 12 months | |
Secondary | Overall survival at 24 months in subset of randomized participants whose PD-L1 status is PD-L1 TC < 1% | OS is defined as the time from randomization until death due to any cause. The measure of interest is survival rate with corresponding 95% CI at 24 months landmark. | At 24 months | |
Secondary | Progression-free survival (PFS) | PFS is defined as the time from randomization until the date of confirmed PD (per Response Evaluation Criteria in Solid Tumours, Version 1.1 [RECIST 1.1] as assessed by the Investigator) or death due to any cause (in the absence of progression) in all participants. | From randomization until disease progression, death, withdrawal of consent, or end of study (approximately 48 months) | |
Secondary | Objective response rate (ORR) | ORR is defined as the proportion of participants with a confirmed objective tumour response (complete response [CR] or partial response [PR]) as determined by the investigator per RECIST 1.1 in all participants who have measurable disease at baseline. | From randomization until disease progression, or the last evaluable assessment in the absence of progression (approximately 48 months) | |
Secondary | Duration of response (DOR) | DOR is defined as the time from the date of first documented confirmed response until the date of documented progression (per RECIST 1.1, as assessed by the Investigator) or death due to any cause (in the absence of disease progression) in all participants who have confirmed objective response. | From first documented response until documented progression (approximately 48 months) | |
Secondary | Time to First Subsequent Therapy (TFST) | TFST is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study intervention, or death due to any cause in all participants. | From randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized study intervention or death [approx. up to 48 months] | |
Secondary | Number of participants with adverse events (AEs) and serious adverse events (SAEs). | To assess the safety and tolerability of durvalumab plus tremelimumab plus chemotherapy compared with pembrolizumab plus chemotherapy in participants with non-squamous histology who have metastatic NSCLC with mutations and/or co-mutations in STK11, KEAP1, or KRAS. | From screening until the follow-up period is completed [approx. up to 48 months] |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |